BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Diabetic Foot Ulcer

Interventions

BIOLOGICAL

BB-101

Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.

Trial Locations (1)

RECRUITING

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, Taipei

All Listed Sponsors

lead

Blue Blood Biotech Corp.

INDUSTRY